MX2015013939A - Composicion farmaceutica, metodos para tratamiento y sus usos. - Google Patents

Composicion farmaceutica, metodos para tratamiento y sus usos.

Info

Publication number
MX2015013939A
MX2015013939A MX2015013939A MX2015013939A MX2015013939A MX 2015013939 A MX2015013939 A MX 2015013939A MX 2015013939 A MX2015013939 A MX 2015013939A MX 2015013939 A MX2015013939 A MX 2015013939A MX 2015013939 A MX2015013939 A MX 2015013939A
Authority
MX
Mexico
Prior art keywords
empagliflozin
therapeutic uses
type
diabetes
ckd
Prior art date
Application number
MX2015013939A
Other languages
English (en)
Inventor
Uli Broedl
Sreeraj Macha
Hans-Juergen Woerle
Maximilian Von Eynatten
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51787230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015013939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2015013939A publication Critical patent/MX2015013939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invención se refiere a determinados inhibidores de SGLT-2 para tratar y/o prevenir trastornos metabólicos, tales como diabetes mellitus tipo 2 o tipo 1, o prediabetes, en pacientes con insuficiencia renal o enfermedad renal crónica (CKD).
MX2015013939A 2013-04-05 2014-04-03 Composicion farmaceutica, metodos para tratamiento y sus usos. MX2015013939A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361808804P 2013-04-05 2013-04-05
CA2812519A CA2812519A1 (en) 2013-04-05 2013-04-10 Pharmaceutical composition, methods for treating and uses thereof
US201361908991P 2013-11-26 2013-11-26
PCT/EP2014/056657 WO2014161919A1 (en) 2013-04-05 2014-04-03 Therapeutic uses of empagliflozin

Publications (1)

Publication Number Publication Date
MX2015013939A true MX2015013939A (es) 2016-07-20

Family

ID=51787230

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013939A MX2015013939A (es) 2013-04-05 2014-04-03 Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2020010004A MX2020010004A (es) 2013-04-05 2015-10-01 Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010004A MX2020010004A (es) 2013-04-05 2015-10-01 Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.

Country Status (15)

Country Link
US (1) US20240066046A1 (es)
EP (2) EP3456332A1 (es)
JP (1) JP6177992B2 (es)
KR (3) KR102318213B1 (es)
CN (2) CN109893534A (es)
AU (1) AU2014247092B2 (es)
CA (3) CA2812519A1 (es)
DK (1) DK2981271T3 (es)
EA (1) EA033397B1 (es)
LT (1) LT2981271T (es)
MX (2) MX2015013939A (es)
PL (1) PL2981271T3 (es)
RS (1) RS58097B1 (es)
SI (1) SI2981271T1 (es)
WO (1) WO2014161919A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CN105769782A (zh) * 2014-12-23 2016-07-20 中美华世通生物医药科技（武汉）有限公司 恩格列净片及其制备方法和用途
CN106880595A (zh) * 2015-12-10 2017-06-23 常州方楠医药技术有限公司 一种无定型依帕列净的固体分散体及其制备方法
CN109922813A (zh) * 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
MX2020003243A (es) 2017-10-02 2020-09-18 Poxel Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
ES2929994T3 (es) 2018-06-06 2022-12-05 Poxel Sa Métodos de tratamiento de sujetos que padecen diabetes con enfermedad renal crónica
MX2020013567A (es) 2018-06-14 2021-05-27 Poxel Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.
CN110141555A (zh) * 2019-06-21 2019-08-20 江苏豪森药业集团有限公司 一种恩格列净片及其制备方法
CN110721170A (zh) * 2019-10-24 2020-01-24 安徽九华华源药业有限公司 一种恩格列净片剂及其制备方法
WO2022065895A1 (ko) * 2020-09-24 2022-03-31 동아에스티 주식회사 Sglt-2 억제제인 엠파글리플로진 유도체의 신규염 및 염의 수화물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000219632A (ja) * 1999-01-28 2000-08-08 Toyotama Koryo Kk カロリー軽減剤
DE102004012676A1 (de) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP2006176443A (ja) * 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
EA018495B1 (ru) * 2006-11-09 2013-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
MX2009011357A (es) * 2007-04-20 2009-11-05 Schering Corp Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
EP2261213A1 (en) * 2008-04-01 2010-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
BRPI1013640A2 (pt) * 2009-02-13 2019-09-24 Boehringer Ingelheim Int composicao farmaceutica, metodos para o tratamento e usos dos mesmos
PT2395968T (pt) * 2009-02-13 2024-03-05 Boehringer Ingelheim Int Composição farmacêutica compreendendo derivados de glucopiranosil difenilmetano, sua forma de dosagem farmacêutica, processo para a sua preparação e suas utilizações para controlo glicémico melhorado num doente
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Also Published As

Publication number Publication date
CN105377267A (zh) 2016-03-02
EP2981271A1 (en) 2016-02-10
MX2020010004A (es) 2020-10-14
SI2981271T1 (sl) 2019-02-28
JP2016515600A (ja) 2016-05-30
KR102318213B1 (ko) 2021-10-28
CA2908635A1 (en) 2014-10-09
CN109893534A (zh) 2019-06-18
LT2981271T (lt) 2019-01-10
JP6177992B2 (ja) 2017-08-09
DK2981271T3 (en) 2019-02-04
EP3456332A1 (en) 2019-03-20
RS58097B1 (sr) 2019-02-28
CA2812519A1 (en) 2014-10-05
EA201500997A1 (ru) 2016-04-29
EA033397B1 (ru) 2019-10-31
KR20230125858A (ko) 2023-08-29
PL2981271T3 (pl) 2019-05-31
CA3121761A1 (en) 2014-10-09
KR20210130844A (ko) 2021-11-01
EP2981271B1 (en) 2018-11-14
KR20150138860A (ko) 2015-12-10
AU2014247092B2 (en) 2018-11-01
AU2014247092A1 (en) 2015-09-17
US20240066046A1 (en) 2024-02-29
CA2908635C (en) 2021-07-13
WO2014161919A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
PH12015502275A1 (en) Therapuetic uses of empagliflozin
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
MX362190B (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2017005884A (es) Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
EP3217987A4 (en) Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
EA201600134A1 (ru) Воласертиб в комбинации с азацитидином для лечения острого миелоидного лейкоза и миелодиспластического синдрома
PH12016501127A1 (en) Adenosine a1 agonists as medicaments against renal diseases
EA201892832A1 (ru) Комбинации линаглиптина и метформина
EA202090141A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин

Legal Events

Date Code Title Description
FG Grant or registration